Implementation of an academic detailing intervention to increase naloxone distribution and foster engagement in harm reduction from the community clinician

Irwin, Adriane N.; Bratberg, Jeffrey; Al-Jammali, Zain; Arnold, Jennifer; Gray, Mary Tod; Floyd, Anthony S.; Bolivar, Derek; Hansen, Ryan N.; Hartung, Daniel; Green, Traci C.

doi:10.1016/j.japh.2022.12.001

Cited by 8 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…106,107 Continuing education is an additional pathway for pharmacist education, and opioid-related content has proliferated in recent years. 56,108 -110 These programs have shown promise for increasing pharmacists’ readiness to provide naloxone and overdose prevention counseling, but further research is needed to investigate their efficacy in conveying OUD treatment knowledge and attitudes, particularly in rural settings where post-graduate professional development may be limited. 111 -113…”

Section: Educational Pathways and Areas For Researchmentioning

confidence: 99%

“…106,107 Continuing education is an additional pathway for pharmacist education, and opioid-related content has proliferated in recent years. 56,[108][109][110] These programs have shown promise for increasing pharmacists' readiness to provide naloxone and overdose prevention counseling, but further research is needed to investigate their efficacy in conveying OUD treatment knowledge and attitudes, particularly in rural settings where post-graduate professional development may be limited. [111][112][113] To prepare pharmacists to offer OUD services, more research needs to be conducted to better characterize the state of OUD education and training in pharmacy schools, post-graduate training, interprofessional programs, and continuing education, and to identify effective interventions to improve OUD education and training.…”

Section: Educational Pathways and Areas For Researchmentioning

confidence: 99%

See 1 more Smart Citation

Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy

Jarrett,

Bratberg,

Burns

et al. 2023

Substance Abuse

View full text Add to dashboard Cite

In the last decade, the U.S. opioid overdose crisis has magnified, particularly since the introduction of synthetic opioids, including fentanyl. Despite the benefits of medications for opioid use disorder (MOUD), only about a fifth of people with opioid use disorder (OUD) in the U.S. receive MOUD. The ubiquity of pharmacists, along with their extensive education and training, represents great potential for expansion of MOUD services, particularly in community pharmacies. The National Institute on Drug Abuse’s National Drug Abuse Treatment Clinical Trials Network (NIDA CTN) convened a working group to develop a research agenda to expand OUD treatment in the community pharmacy sector to support improved access to MOUD and patient outcomes. Identified settings for research include independent and chain pharmacies and co-located pharmacies within primary care settings. Specific topics for research included adaptation of pharmacy infrastructure for clinical service provision, strategies for interprofessional collaboration including health service models, drug policy and regulation, pharmacist education about OUD and OUD treatment, including didactic, experiential, and interprofessional curricula, and educational interventions to reduce stigma towards this patient population. Together, expanding these research areas can bring effective MOUD to where it is most needed.

show abstract

Section: Educational Pathways and Areas For Researchmentioning

confidence: 99%

Section: Educational Pathways and Areas For Researchmentioning

confidence: 99%

Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy

Jarrett,

Bratberg,

Burns

et al. 2023

Substance Abuse

View full text Add to dashboard Cite

show abstract

“…R2P aimed to increase the distribution of naloxone, buprenorphine dispensing and to promote the sale of NPS ( Green et al, 2022 ). The intervention included three online self-guided trainings, in-person academic detailing, and educational material supports to community pharmacies to expand access to harm reduction resources ( Irwin et al, 2023 ). The study includes online and one-on-one educational outreach (i.e.…”

Section: Introductionmentioning

confidence: 99%

Policies, adaptations, and ongoing challenges to naloxone, buprenorphine and nonprescription syringe access across four-states: Findings from an environmental scan and key informant interviews

Floyd,

Silcox,

Strickler

et al. 2024

Drug and Alcohol Dependence Reports

Self Cite

View full text Add to dashboard Cite

Association of economic and racial segregation with restricted buprenorphine dispensing in U.S. community pharmacies

Moon,

Linton,

Kazerouni

et al. 2024

Drug and Alcohol Dependence Reports

View full text Add to dashboard Cite

Implementation of an academic detailing intervention to increase naloxone distribution and foster engagement in harm reduction from the community clinician

Cited by 8 publications

References 30 publications

Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy

Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy

Policies, adaptations, and ongoing challenges to naloxone, buprenorphine and nonprescription syringe access across four-states: Findings from an environmental scan and key informant interviews

Association of economic and racial segregation with restricted buprenorphine dispensing in U.S. community pharmacies

Contact Info

Product

Resources

About